Denosumab
Also known as: Prolia, denosumab injection
A monoclonal antibody biologic used for the approach of osteoporosis in postmenopausal women at high risk of fracture, and for those who cannot tolerate bisphosphonates. Administered as a subcutaneous injection every six months by a healthcare professional.
This page contains self-reported experiences from the Narrated community — not clinical data. Outcomes are subjective. Always consult your doctor or specialist before starting, stopping, or changing any approach.
Regulatory status is factual context, not a clinical-risk assessment. Laws vary by country.
Community Experiences
0 reports from women who tried Denosumab
No one has reported on this approach yet.
Be the first to share an experience.
Research Context
Research context compiled from published sources
How does Denosumab work?
Binds to RANKL (receptor activator of nuclear factor kappa-B ligand), preventing it from activating RANK on osteoclast precursors. This inhibits osteoclast formation, function, and survival, markedly reducing bone resorption. Results in significant increases in bone mineral density at all skeletal sites.
Research Depth
Well Studied
Extensive human research over many years, including randomized controlled trials.
Long-Term Evidence
Well Characterized
Decades of long-term human-use data are available.
Known Interactions
Reported Contraindicated Populations
Published Dose Ranges
Dose ranges from published research. Individual dosing is context-specific and belongs in a healthcare conversation.
Factual research context from published sources — not a clinical-risk assessment or guidance. Research classifications may change as new data emerges.
Related Approaches
Other approaches tracked on Narrated.
Data last updated: No data yet